Andrea Necchi, Associate Editor at Journal of Clinical Oncology, posted the following on X:
“Happy to share this innovative phase I (TEM-GU) study is now active and recruiting patients with metastatic clear cell RCC who have a disease progressing after at least 2 lines of treatment including IO and a VEGF-TKI.
Temferon is a gene therapy with hematopoietic stem cells designed to reprogram the tumor microenvironment by delivering immunomodulatory molecules directly to tumors.”